Novo Nordisk, the world leader in insulin products, took a big hit this year when the FDA denied approval of its newest long-lasting insulin drug, Tresiba. But CEO Lars Rebien Sørensen is taking every opportunity to let the markets know that Novo has lots of growth in its business.
Despite a major setback earlier this year when the FDA rejected Novo Nordisk's application for Tresiba, forcing a new cardio study, the Danish pharma company's CEO is boasting that the company has a strong R&D effort underway.
Novo Nordisk won the endorsement of a key European regulatory committee for a device designed to work in tandem with a Roche insulin pump to help simplify treatment for diabetics. A CE marking is likely and could open lucrative doors for both companies.
Danish diabetes care giant Novo Nordisk won FDA approval this week for two of its FlexTouch prefilled insulin pens, the NovoLog and Levemir.
With a respectable sales increase and profits growth that beat Big Pharma's, Novo Nordisk's third-quarter results still fell short of analyst expectations. The reason: Novo's powerhouse diabetes drug Victoza is slowing down a bit.
Danish drugmaker Novo Nordisk is recalling 33 batches of insulin pens in the U.K. because of a manufacturing issue that led to a very small number of them having a very large disparity in their insulin fills.
The spectacular, $90 million burglary of a warehouse full of Eli Lilly drugs in 2010 continues to be in the news as some of the two dozen suspects get charged or convicted.
Novo Nordisk is known for its dominance in the diabetes market. The company sports 5 of the 10 top-selling diabetes remedies worldwide. But the company has a stash of other treatments, and it just added one to the mix. The FDA gave its blessing to Novo's new factor VIII treatment for hemophilia A, NovoEight.
Novo Nordisk has secured FDA approval for Novoeight, a hemophilia A biologic the drugmaker hopes will help make up for the slumping sales of an aging giant and dull the blow of impending competition.
It seemed like a match made in heaven. A few years ago, as the patent cliff neared and drugmakers were looking for new sources of revenue, market researchers were toting up growth prospects around...